SITE SEARCH
DOWNLOAD
EMAIL UPDATES
Want to keep on top of what's going on in our community? It's easy! SIGN UP TODAY for the Dallas Voice's weekly Email update and have the latest news and information sent directly to you.
EMAIL ADDRESS
EMAIL ADDRESS
Last Updated: Jul 7, 2008 - 10:08:41 AM
Bristol-Meyers Squibb, Gilead advance single-dose HIV drug
By Staff and Wire reports
Jan 12, 2006 - 9:55:00 PM
Drug makers Bristol-Meyers Squibb Com-pany and Gilead Sciences announced Monday that a pill combining their two HIV treatments provided the equivalent to the two therapies taken separately.
The companies plan to file an application for the combination drug with U.S. regulators in the second quarter of the year, officials said.
The new combination drug will combine Bristol-Meyers' Sustiva with Gilead's Truvada in a one-pill fixed dose, using a process called "bi-layer" technology.
The companies plan to file an application for the combination drug with U.S. regulators in the second quarter of the year, officials said.
The new combination drug will combine Bristol-Meyers' Sustiva with Gilead's Truvada in a one-pill fixed dose, using a process called "bi-layer" technology.
© Copyright by DallasVoice.com
Top of Page
